Roche’s Lunsumio Combination Meets Primary Endpoint in Phase III CELESTIMO Trial for Relapsed or Refractory Follicular Lymphoma Roche has announced positive topline results from the Phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide in people with relapsed…
Novo Nordisk’s FREHEMGO Receives Positive CHMP Opinion for Haemophilia A Novo Nordisk has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorisation for FREHEMGO®…
Puma Biotechnology Initiates Phase II ALISCA®-Lung2 Trial of Alisertib and Paclitaxel in Advanced Small Cell Lung Cancer Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company focused on developing innovative cancer therapies, has announced the initiation of its Phase II ALISertib…
Guardant Health’s Shield Blood Test Gains EviCore Coverage, Expanding Access to Colorectal Cancer Screening Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its Shield™ blood test for colorectal cancer (CRC) screening will be included in EviCore…
Bristol Myers Squibb Reports Positive Phase 2 QUINTESSENTIAL Results for Arlo-Cel in Heavily Pretreated Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) announced positive Phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel (arlo-cel; BMS-986393) in adults with quadruple-class…
Novartis Reports HARBOR Phase 3 Study of Del-Desiran in Myotonic Dystrophy Type 1 Misses Primary Endpoint Novartis announced that the global Phase 3 HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) did not achieve its…
MEDIPAL and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for MPS IIIB MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. (TSE: 4552) announced that the first participant has been dosed in the global Phase I/II…
BioLab Holdings Expands Placental Membrane Portfolio With New Membrane Wrap Amniotic Hydro BioLab Holdings, Inc., a Phoenix-based medical technology company focused on tissue restoration, has expanded its portfolio of placental membrane products with the addition of Membrane Wrap™ Amniotic Hydro.…
PureTech Health Notes Positive Phase 1 Driving Trial Results for GlyphAllo in Major Depressive Disorder PureTech Health plc (LSE: PRTC), a biotherapeutics company operating through a hub-and-spoke model to translate scientific innovation into potentially transformative medicines, has highlighted positive topline…
TRIANA Biomedicines Publishes Nature Study Supporting TRI-611 Molecular Glue Therapy for ALK-Positive NSCLC TRIANA Biomedicines, Inc. (TRIANA), a clinical-stage biopharmaceutical company focused on developing molecular glue therapies against difficult-to-drug disease targets, has announced the publication of new preclinical research supporting…
PhenoNet Completes Enrollment in Phase IIb Trial of PHENOGENE-1A for ALS PhenoNet, Inc., a clinical-stage biotechnology company developing investigational therapies for neurodegenerative diseases, has announced the completion of recruitment and randomization in its Phase IIb clinical trial evaluating PHENOGENE-1A as…
Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-663 for Multiple Cancers Crossbow Therapeutics, Inc., a biotechnology company developing targeted antibody therapies designed to address a broad range of cancers, has announced the dosing of the first participant…